Compare AES Corp (AES) vs Zoetis Inc (ZTS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AES Corp vs Zoetis Inc — how do they compare? AES Corp trades at $14.65 (market cap $10.43B), while Zoetis Inc trades at $75.79 (market cap $31.62B). The key difference: Zoetis Inc is far larger — about 3× AES Corp's market cap, and AES Corp pays the higher dividend (4.81%). Which is the better fit depends on your goals.
| AES | ZTS | |
|---|---|---|
Market Cap | $10.43B | $31.62B |
Sector | Utilities | Health |
52-Week High | $17.28 | $158.80 |
52-Week Low | $11.07 | $71.91 |
Enterprise Value | $39.77B | $38.92B |
Dividend Yield | 4.81% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AES trades at $14.62, up 0.27% on the day, with strong fundamentals including a P/E of 7.59 and net income margin of 10.82%. Recent quarters show consistent earnings beats, while technical indicators signal bearish momentum. The company's pending $33.4 billion acquisition by a BlackRock/EQT consortium, approved by stockholders on June 26, 2026, caps near-term upside at $15 per share but provides a stable exit pathway.
The investment case hinges on the acquisition closing, offering a 2.6% gain to the $15 buyout price plus dividend yield. Risks include deal completion uncertainty and shareholder litigation. With no sell-side analysts recommending sell, the stock presents a low-risk arbitrage opportunity with defined upside and limited downside if the transaction proceeds as planned.
Zoetis (ZTS) trades at $76.29, up 1.99% on the day, with a bearish technical signal from moving averages. The company maintains strong profitability with a 28.03% net income margin and 67.75% ROE, though Q1 2026 earnings missed expectations. Recent news highlights multiple class-action lawsuits filed against the company, creating investor uncertainty despite a consensus analyst price target of $101.43.
The stock presents a valuation opportunity with a P/E of 12.36 below industry averages, but faces near-term headwinds from legal challenges and mixed earnings performance. Upside potential exists if the company can overcome litigation concerns and return to consistent earnings beats, while downside risk persists from ongoing legal proceedings and competitive pressures in the animal health market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AES Corp
AES is a global power company operating across 14 countries and 4 continents. Its current generation portfolio as of year-end 2021 consists of over 31 gigawatts of generation, with the generation mix composed of renewables (43%), gas (32%), coal (23%), and oil (2%). The company has 3.5 gigawatts of generation under construction. AES has majority ownership and operates six electric utilities distributing power to 2.6 million customers.
Read more on AES →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
